
The healthcare sector had a rough couple of days at the end of last week, as news regarding the Trump administration's new stance on the status of rebates collected by pharmacy benefit managers. This is yet another bit of negative political news for the drug makers, adding to the fear surrounding this space as we creep closer to the 2020 election where healthcare reform will most definitely be a major issue. And, on top of it all, on Friday news broke that the DOJ was launching a criminal probe focused on Johnson & Johnson's (NYSE:JNJ) talc powder/asbestos issues. This caused JNJ's losses to accelerate, and although the company bounced off of the intra-day lows a bit, shares still closed the week at their lowest levels since early June.
Anytime a dividend aristocrat like JNJ sells off, my ears perk up a bit. This is a high-quality company that has been generating massive wealth for shareholders for decades now. It's a core-type buy-and-hold position for many dividend growth investors and now that shares are nearing recent support levels, I wanted to take a closer look at the stock.
READ FULL ARTICLE HERE

